TXGNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31

10x Genomics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026

$69.89+0.03 (+0.04%)

Close on Oct 19, 2026

Market cap: $9.08B
P/E (TTM): –
Dividend yield: –

10x Genomics, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31
Depreciation & Amortization	36	36	36	25	21	14	7.07	3.91	4.31
Stock-Based Compensation	109	141	167	137	96	49	13	2.66	1.66
Deferred Income Taxes	-0.31	0.71	-0.45	0.14	-0.69	0.08	-0.01	–	–
Change in Accounts Receivable	41	27	-11	-19	-34	-18	-5.28	-15	-5.13
Change in Inventory	28	-9.78	7.87	-21	-30	-15	-6.70	-3.73	-2.00
Change in Accounts Payable	-2.13	-3.35	-6.02	5.86	11	-7.77	4.90	2.59	3.03
Change in Unearned Revenue	0.75	11	11	3.35	1.54	2.02	0.63	1.67	1.32
Operating Cash Flow	136	6.66	-15	-34	-21	-218	35	-76	-11
Capital Expenditures	-5.94	-12	-49	-132	-101	-37	-43	-6.28	-3.76
Acquisitions	–	0	0	-4.00	-5.45	0	0	–	–
Purchase of Investments	-123	-49	0	-283	0	0	–	–	–
Sale & Maturity of Investments	125	26	83	19	0	0	–	–	–
Investing Cash Flow	-13	-33	133	-351	-107	-38	-43	-6.71	-3.76
Share Repurchases	–	–	–	–	–	–	–	–	-0.08
Stock Issued	–	–	–	0	0	482	411	0	–
Debt Issued	–	–	–	–	–	0	0	20	–
Debt Repaid	–	–	–	0	0	-31	0	-0.70	–
Financing Cash Flow	6.80	11	14	16	35	469	415	105	21
Foreign Exchange Rate Adjustments	0.48	-0.16	-0.03	-0.04	0.23	-0.46	-0.05	-0.02	-0.01
Net Change in Cash	130	-15	132	-369	-93	212	406	22	6.11
Free Cash Flow	130	-5.73	-64	-165	-123	-255	-8.12	-83	-14
Income Taxes Paid	2.39	5.64	4.93	3.93	8.66	0.28	0.02	0.01	–
Interest Paid	0	0	0.44	0.84	1.22	1.67	2.25	1.82	0.66

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 70.0%
Operating margin: -14.3%
Net margin: -12.2%
Return on equity, FY2025: -5.8%

Financial strength

Current ratio: 5.69
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 424.0%

Valuation

P/E ratio: –
Price to sales: 14.73
Price to book: 11.00
Dividend yield: –